Our laboratory engages in both translational and clinical research projects. We have an active protocol collecting biospecimens from patients undergoing checkpoint blockade to test our hypotheses. Biomarker development based on combinations of immune cells to predict response to immunotherapy is underway. The first immune score for ipilimumab was published in Frontiers in Immunology. Additionally, we completed the first-in-human trial in collaboration with the company Morphogenesis describing the use of a new plasmid for melanoma patients published in Cancer Immunology, Immunotherapy.
In the figure below we illustrate survival curves for patients with distinct nitric oxide phenotypes in patients receiving ipilimumab therapy.